|
1
|
Janney A, Powrie F and Mann EH:
Host-microbiota maladaptation in colorectal cancer. Nature.
585:509–517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johdi NA and Sukor NF: Colorectal cancer
immunotherapy: Options and strategies. Front Immunol. 11:16242020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmoll HJ, Van Cutsem E, Stein A,
Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde
CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for
management of patients with colon and rectal cancer. A personalized
approach to clinical decision making. Ann Oncol. 23:2479–2516.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D; ESMO Guidelines Working Group, : Metastatic
colorectal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii1–iii9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoshino T, Arnold D, Taniguchi H,
Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh
KH, et al: Pan-Asian adapted ESMO consensus guidelines for the
management of patients with metastatic colorectal cancer: A
JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann
Oncol. 29:44–70. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bonjer HJ, Deijen CL, Abis GA, Cuesta MA,
van der Pas MH, de Lange-de Klerk ES, Lacy AM, Bemelman WA,
Andersson J, Angenete E, et al: A randomized trial of laparoscopic
versus open surgery for rectal cancer. N Engl J Med. 372:1324–1332.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
MacFarlane JK, Ryall RD and Heald RJ:
Mesorectal excision for rectal cancer. Lancet. 341:457–460. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park SC, Sohn DK, Kim MJ, Chang HJ, Han
KS, Hyun JH, Joo J and Oh JH: Phase II clinical trial to evaluate
the efficacy of transanal endoscopic total mesorectal excision for
rectal cancer. Dis Colon Rectum. 61:554–560. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garg MB, Lincz LF, Adler K, Scorgie FE,
Ackland SP and Sakoff JA: Predicting 5-fluorouracil toxicity in
colorectal cancer patients from peripheral blood cell telomere
length: A multivariate analysis. Br J Cancer. 107:1525–1533. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogura A, Konishi T, Cunningham C,
Garcia-Aguilar J, Iversen H, Toda S, Lee IK, Lee HX, Uehara K, Lee
P, et al: Neoadjuvant (chemo) radiotherapy with total mesorectal
excision only is not sufficient to prevent lateral local recurrence
in enlarged nodes: Results of the multicenter lateral node study of
patients with low cT3/4 rectal cancer. J Clin Oncol. 37:33–43.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patel JN: Application of genotype-guided
cancer therapy in solid tumors. Pharmacogenomics. 15:79–93. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pellino G, Gallo G, Pallante P, Capasso R,
De Stefano A, Maretto I, Malapelle U, Qiu S, Nikolaou S, Barina A,
et al: Noninvasive biomarkers of colorectal cancer: Role in
diagnosis and personalised treatment perspectives. Gastroenterol.
2018:23978632018.PubMed/NCBI
|
|
17
|
Ogunwobi OO, Mahmood F and Akingboye A:
Biomarkers in colorectal cancer: Current research and future
prospects. Int J Mol Sci. 21:53112020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patel JN, Fong MK and Jagosky M:
Colorectal cancer biomarkers in the era of personalized medicine. J
Pers Med. 9:32019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yiu AJ and Yiu CY: Biomarkers in
colorectal cancer. Anticancer Res. 36:1093–1102. 2016.PubMed/NCBI
|
|
20
|
Zong S, Dai W, Fang W, Guo X and Wang K:
SIK2 promotes cisplatin resistance induced by aerobic glycolysis in
breast cancer cells through PI3K/AKT/mTOR signaling pathway. Biosci
Rep. May 27–2020.(Epub ahead of Print).
|
|
21
|
Zhao J, Zhang X, Gao T, Wang S, Hou Y,
Yuan P, Yang Y, Yang T, Xing J, Li J and Liu S: SIK2 enhances
synthesis of fatty acid and cholesterol in ovarian cancer cells and
tumor growth through PI3K/Akt signaling pathway. Cell Death Dis.
11:252020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun Z, Niu S, Xu F, Zhao W, Ma R and Chen
M: CircAMOTL1 promotes tumorigenesis through miR-526b/SIK2 axis in
cervical cancer. Front Cell Dev Biol. 8:5681902020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oughtred R, Rust J, Chang C, Breitkreutz
BJ, Stark C, Willems A, Boucher L, Leung G, Kolas N, Zhang F, et
al: The BioGRID database: A comprehensive biomedical resource of
curated protein, genetic, and chemical interactions. Protein Sci.
30:187–200. 2021. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Xu X, Jiang Y, Hansbro NG, Hansbro
PM, Xu J and Liu G: Elastin is a key factor of tumor development in
colorectal cancer. BMC Cancer. 20:2172020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mauri G, Sartore-Bianchi A, Russo AG,
Marsoni S, Bardelli A and Siena S: Early-onset colorectal cancer in
young individuals. Mol Oncol. 13:109–131. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang X, Zhang H, Shen B and Sun XF:
Chromogranin-A expression as a novel biomarker for early diagnosis
of colon cancer patients. Int J Mol Sci. 20:29192019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Doll R and Peto R: The causes of cancer:
Quantitative estimates of avoidable risks of cancer in the United
States today. J Natl Cancer Inst. 66:1191–1308. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rothschild D, Weissbrod O, Barkan E,
Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN,
Bar N, et al: Environment dominates over host genetics in shaping
human gut microbiota. Nature. 555:210–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liang Q, Chiu J, Chen Y, Huang Y,
Higashimori A, Fang J, Brim H, Ashktorab H, Ng SC, Ng SSM, et al:
Fecal bacteria act as novel biomarkers for noninvasive diagnosis of
colorectal cancer. Clin Cancer Res. 23:2061–2070. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ladabaum U, Dominitz JA, Kahi C and Schoen
RE: Strategies for colorectal cancer screening. Gastroenterology.
158:418–432. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cuezva JM, Ortega AD, Willers I,
Sánchez-Cenizo L, Aldea M and Sánchez-Aragó M: The tumor suppressor
function of mitochondria: Translation into the clinics. Biochim
Biophys Acta. 1792:1145–1158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vander Heiden MG, Lunt SY, Dayton TL,
Fiske BP, Israelsen WJ, Mattaini KR, Vokes NI, Stephanopoulos G,
Cantley LC, Metallo CM and Locasale JW: Metabolic pathway
alterations that support cell proliferation. Cold Spring Harb Symp
Quant Biol. 76:325–334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lunt SY and Vander Heiden MG: Aerobic
glycolysis: Meeting the metabolic requirements of cell
proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Enzo E, Santinon G, Pocaterra A, Aragona
M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo
G, et al: Aerobic glycolysis tunes YAP/TAZ transcriptional
activity. EMBO J. 34:1349–1370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Samec M, Liskova A, Koklesova L, Samuel
SM, Zhai K, Buhrmann C, Varghese E, Abotaleb M, Qaradakhi T, Zulli
A, et al: Flavonoids against the warburg phenotype-concepts of
predictive, preventive and personalised medicine to cut the Gordian
knot of cancer cell metabolism. EPMA J. 11:377–398. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao T, Zhang X, Zhao J, Zhou F, Wang Y,
Zhao Z, Xing J, Chen B, Li J and Liu S: SIK2 promotes reprogramming
of glucose metabolism through PI3K/AKT/HIF-1α pathway and
Drp1-mediated mitochondrial fission in ovarian cancer. Cancer
Letters. 469:89–101. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin LF, Li CF, Wang WJ, Yang WM, Wang DD,
Chang WC, Lee WH and Wang JM: Loss of ZBRK1 contributes to the
increase of KAP1 and promotes KAP1-mediated metastasis and invasion
in cervical cancer. PLoS One. 8:e730332013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yokoe T, Toiyama Y, Okugawa Y, Tanaka K,
Ohi M, Inoue Y, Mohri Y, Miki C and Kusunoki M: KAP1 is associated
with peritoneal carcinomatosis in gastric cancer. Ann Surg Oncol.
17:821–828. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang YY, Li L, Zhao ZS and Wang HJ:
Clinical utility of measuring expression levels of KAP1, TIMP1 and
STC2 in peripheral blood of patients with gastric cancer. World J
Surg Oncol. 11:812013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qi ZX, Cai JJ, Chen LC, Yue Q, Gong Y, Yao
Y and Mao Y: TRIM28 as an independent prognostic marker plays
critical roles in glioma progression. J Neurooncol. 126:19–26.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fitzgerald S, Sheehan KM, O'Grady A, Kenny
D, O'Kennedy R, Kay EW and Kijanka GS: Relationship between
epithelial and stromal TRIM28 expression predicts survival in
colorectal cancer patients. J Gastroenterol Hepatol. 28:967–974.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fitzgerald S, Espina V, Liotta L, Sheehan
KM, O'Grady A, Cummins R, O'Kennedy R, Kay EW and Kijanka GS:
Stromal TRIM28-associated signaling pathway modulation within the
colorectal cancer microenvironment. J Transl Med. 16:892018.
View Article : Google Scholar : PubMed/NCBI
|
